Early versus late hormonal therapy for prostate cancer.
Hormonal therapy remains the critical therapeutic option for men with advanced prostate cancer. However, considerable uncertainty remains regarding the appropriate choice/timing and actual benefits of hormonal therapy in various situations. This article reviews the relevant studies of immediate versus deferred hormonal therapy in patients with prostate cancer. The evidence from the data supports that early treatment is beneficial to many patients. Significant survival benefit of early hormonal therapy has been observed among patients with asymptomatic metastatic disease, node-positive but clinically localized disease after radical prostatectomy and lymphadenectomy, and advanced local/regional disease during and after radiotherapy.
Miyamoto
Hiroshi
H
Department of Urology, University of Rochester, 601 Elmwood Avenue, Box 656, Rochester, NY 14642, USA.
Messing
Edward M
EM
D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D006801:Humans; D008297:Male; D009362:Neoplasm Metastasis; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology*; D015996:Survival Rate
D018931:Antineoplastic Agents, Hormonal